Aurinia Launches Resource Kit for People Living With Lupus Nephritis & Partners With National Kidney Foundation on Awareness ...
March 12 2020 - 7:00AM
Business Wire
- Company recognizes World Kidney Day and
National Kidney Month -
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”) , a late-stage clinical biopharmaceutical company
focused on advancing voclosporin across multiple inflammatory and
autoimmune conditions, today announced new initiatives to support
the lupus nephritis (LN) community and raise disease awareness on
World Kidney Day, during National Kidney Month and beyond. These
initiatives and resources include:
- #ALLINorange: Through the ALL IN program, Aurinia is
once again partnering with the National Kidney Foundation (NKF) on
its #ALLINorange campaign throughout the month of March to raise
awareness and understanding of LN. The ALL IN program is a source
of information, resources, and support for those affected by LN and
their care partners. ALL IN community members and those who newly
register in March will receive #ALLINorange disease awareness
bracelets to show support for National Kidney Month and the LN
community. More information is available at
www.allinforln.com.
- ALL IN Lupus Nephritis Awareness Resource Kit: Aurinia
also launched today a new resource kit for people living with LN
and their care partners. The kit was created with input from
members of the LN community to help expand awareness and knowledge
of lupus nephritis. The resource kit is available at
www.allinforln.com/awarenesskit.
There is currently no FDA-approved therapy for LN, which is
inflammation of the kidneys caused by systemic lupus erythematosus
(SLE) and represents a serious progression of SLE. LN affects up to
50% of the SLE patient population.
“Observances such as National Kidney Month and World Kidney Day
are a reminder that people living with lupus nephritis are affected
by the severe symptoms and complications associated with this
disease each and every day. We are honored to work together with
the community to advance understanding of this serious disease,”
said Neil Solomons, M.D. Chief Medical Officer at Aurinia. “The ALL
IN program is a source of information, resources, and support for
those affected by LN, and we are committed to continuing to build
on materials and initiatives that benefit the community.”
More information about LN is available at www.allinforln.com.
Members of the LN community can also find and share these resources
and information about LN on Facebook @AuriniaPharma during National
Kidney Month.
About Lupus Nephritis
Lupus nephritis (LN) is an inflammation of the kidney caused by
Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. SLE is a chronic, complex and often disabling
disorder. The disease is highly heterogeneous, affecting a wide
range of organs and tissue systems. Unlike SLE, LN has
straightforward disease outcomes (measuring proteinuria) where an
early response correlates with long-term outcomes. In patients with
LN, renal damage results in proteinuria and/or hematuria and a
decrease in renal function as evidenced by reduced eGFR, and
increased serum creatinine levels. LN is debilitating and costly
and if poorly controlled, LN can lead to permanent and irreversible
tissue damage within the kidney, resulting in end-stage renal
disease (ESRD), thus making LN a serious and potentially
life-threatening condition.
About Aurinia
Aurinia Pharmaceuticals is a late clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are impacted
by diseases with a high unmet medical need. The Company is
currently developing an investigational drug for the treatment of
lupus nephritis, focal segmental glomerulosclerosis and dry eye
syndrome. The Company’s head office is in Victoria, British
Columbia and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.
About National Kidney Foundation
The National Kidney Foundation (NKF) is the largest, most
comprehensive, and longstanding patient-centric organization
dedicated to the awareness, prevention, and treatment of kidney
disease in the U.S. For more information about NKF, visit
www.kidney.org.
Forward-Looking Statement
Certain of the statements made in this presentation may
constitute forward-looking information within the meaning of
applicable Canadian securities law and forward-looking statements
within the meaning of applicable U.S. securities law. These
forward-looking statements or information include but are not
limited to statements or information with respect to lupus
nephritis (LN), FSGS and Dry Eye Syndrome.
Forward-looking information by their nature are based on
assumptions and involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of Aurinia to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking information. Should one or more of these risks and
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described
in forward-looking statements or information. Accordingly, you
should not place undue reliance on forward-looking statements or
information.
Except as required by law, Aurinia will not update
forward-looking information. All forward-looking information
contained in this presentation is qualified by this cautionary
statement. Additional information related to Aurinia, including a
detailed list of the risks and uncertainties affecting Aurinia and
its business can be found in Aurinia’s most recent Annual
Information Form available by accessing the Canadian Securities
Administrators’ System for Electronic Document Analysis and
Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities
and Exchange Commission’s Electronic Document Gathering and
Retrieval System (EDGAR) website at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200312005222/en/
Investors & Corporate: Glenn Schulman, PharmD, MPH
Corporate Communications, Aurinia gschulman@auriniapharma.com
Media: Krystle Gibbs Ten Bridge Communications
krystle@tenbridgecommunications.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024